Study to Evaluate ACDN-01 in ABCA4-related Retinopathy (STELLAR)

NCTID	NCT06467344 (View at clinicaltrials.gov)
Description	This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01. (Show More)
Indication	Stargardt Disease
Compound Name	ACDN-01
Sponsor	Ascidian Therapeutics, Inc
Funder Type	Industry
Status	Recruiting
Enrollment Count	13

No.of Trial Sites	10
Locations	United States

Has US IND	True
Recent Updates	Rare Pediatric Disease designation granted 4/25/24